RxDoctor Payments Data

Jan Schroeder

Family · Lima, OHNPI 1710015680

Payments from drug & device makers

$973in general payments, 2019–2025

Across 21 payments — averaging $46.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$342
  • Amgen$127
  • W. L. Gore & Associates, Inc.$116
  • Johnson & Johnson$115
  • Ultragenyx Pharmaceutical Inc.$88
  • Inspire Medical Systems, Inc.$55
  • plus $130 from 5 others

What the payments were for

  • Food & beverage$973100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$973 in reported general payments places this provider in the 70th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$55,129
Medicare patients
142
Services billed
893

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide138$160,680
JardianceEmpagliflozin106$109,082
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$87,960
JanuviaSitagliptin Phosphate66$82,003
FarxigaDapagliflozin Propanediol45$54,587
OzempicSemaglutide48$49,031
TrulicityDulaglutide29$35,895
MyrbetriqMirabegron39$29,425
EliquisApixaban23$19,779
Breo ElliptaFluticasone/Vilanterol31$18,092
Incruse ElliptaUmeclidinium Bromide21$14,427
LinzessLinaclotide13$14,180
Spiriva HandihalerTiotropium Bromide12$13,891
XareltoRivaroxaban35$13,127
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$11,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$16$196,575167 claims
AstraZenecaFarxiga, Symbicort$342$59,33856 claims
PfizerEliquis, Premarin$34$25,73842 claims
Johnson & JohnsonXarelto$115$13,12735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,812 family providers in Ohio.

Other family in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →